Highest-materiality recent filing
CapsoVision enters ATM sales agreement with Cantor Fitzgerald for up to $100M
At-the-market program allows sale of up to $100M of common stock via Cantor Fitzgerald as sales agent.
CapsoVision Q2 revenue $3.6M (+10% YoY), gross margin 51%, ATM up to $100M
Q2 revenue $3.6M, up 10% YoY; gross margin 51% vs 55% on pricing pressure and tariffs.
CapsoVision appoints Dr. David Shields to board; Dr. Imperial resigns but remains consultant
Dr. David Shields, a gastroenterologist with 40+ years experience and capsule endoscopy pioneer, appointed Class I director and Compensation Committee member effective July 1, 2026.
CapsoVision stockholders re-elect three Class I directors, ratify Baker Tilly as auditor
Joanne Imperial, M.D. re-elected with 32,060,734 votes for and 70,447 withheld (2,244,596 broker non-votes).
CapsoVision Q1 revenue flat at $2.8M; gross margin slides to 48% on tariffs
Total revenue $2.8M, flat YoY; capsule volume down 3% offset by higher ASP.
CapsoVision reports 15% revenue growth in FY2025; completes $14M private placement
Q4 2025 revenue $3.9M (+13% YoY); full year $13.6M (+15% YoY) driven by higher capsule sales.
CapsoVision closes $14M private placement; reports preliminary FY2025 revenue of $13.6M
Raised $14M gross via 2.87M shares at $4.883 (5% discount to March 16 close); closed March 16, 2026.
CapsoVision amends Canon development deal; total fee increased by $1.0M
Total fee under CMOS image sensor development agreement with Canon raised by $1.0M due to increased features.
CapsoVision submits 510(k) to FDA for AI-assisted reading module for CapsoCam Plus
Submitted 510(k) to FDA for proprietary AI-assisted module for CapsoCam Plus capsule endoscopy system.
CapsoVision Q3 revenue $3.5M (+19% YoY); FDA submission for pancreatic cancer capsule
Revenue $3.5M (+19% YoY); new accounts up 31%; CapsoCam Plus used by 151k patients.
CapsoVision files FDA Breakthrough Device application for pancreatic cancer screening capsule
Submitted BDD application to FDA on Nov 6, 2025 for CapsoCam UGI capsule to detect early-stage pancreatic ductal adenocarcinoma.
CapsoVision appoints David Garcia as SVP of Finance and principal financial officer
Effective Nov 3, 2025; Garcia previously VP of FP&A at Matterport, led IPO and M&A.
CapsoVision Senior Director of Clinical Affairs to retire; Keri Jorgenson promoted
Rebecca Petersen to retire as Senior Director of Clinical Affairs effective Oct 15, 2025.
CFO Kevin Lundquist steps down; CapsoVision begins successor search
Kevin Lundquist resigned as CFO effective Aug 27, 2025; company started search for replacement.
CapsoVision Q2 revenue $3.3M (+17% YoY); IPO closes raising $23.4M
Revenue $3.3M, up 17% YoY, driven by higher CapsoCam Plus capsule sales.
CapsoVision signs $4.1M CMOS sensor development agreement with Canon; overallotment yields $0.6M
Development agreement with Canon for CMOS image sensor samples; total fee ~$4.1M, $1M cash upfront, remainder via unit price add-on in future purchase agreement.
CapsoVision closes IPO of 5.5M shares at $5.00; gross proceeds $27.5M
Completed IPO of 5,500,000 shares at $5.00/share, raising $27.5M in gross proceeds.
On July 1, 2026, the Board of Directors (the “Board”) of CapsoVision Inc. (the “Company”) appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board
On July 1, 2026, Dr. Joanne Imperial stepped down from the Board as a Class I director and as a member of the Compensation Committee of the Board, effective immediately.
Max materiality 0.75 · Median 0.60 · Most common event other_material